CliffBio
small molecule

ABRAXANE

PACLITAXEL

Loss of exclusivityJuly 2034latest FDA-listed patent expiry
CompanyBristol-Myers Squibb →See this company's full patent-cliff portfolio

Drug detail

Brand nameABRAXANE
Active ingredientPACLITAXEL
Strength100MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 2005
Marketing statusRX

Listed patents

PatentExpiresType
9511046*PEDJuly 2034—
9511046January 2034use U-1434
9393318*PEDSeptember 2032—
9597409*PEDSeptember 2032—
9393318March 2032use U-1290
9597409March 2032use U-1290
8034375*PEDFebruary 2027—
9101543*PEDAugust 2026—
8268348*PEDAugust 2026—
7758891*PEDAugust 2026—
8034375August 2026use U-1290
7758891February 2026use U-1434
9101543February 2026use U-1434
8268348February 2026use U-1290

More from Bristol-Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABRAXANE patent cliff — loss of exclusivity July 2034 | CliffBio